Shares of Oruka Therapeutics Inc. (ORKA) are down nearly 48% from their 52-week high of $31.13, recorded last October, and trade around $16.
This biotechnology company is developing novel biologics for chronic skin diseases. Its lead investigational biologics, ORKA-001 and ORKA-002, are designed to block cytokines that play key roles in the pathogenesis of psoriasis and other inflammatory diseases.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.